ADGMADGMHealthcare · Medical Devices

ADGM Stock Forecast: Adagio Medical Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.75
+5.42% on the day

The median 12-month analyst price target for Adagio Medical Holdings, Inc. is $120. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.7M
Ticker Nerd rank
24/ 100
Median analyst target
$120
Analysts covering
1
Revenue$0.0
Operating income−$4.9M
Net income−$6.7M
Free cash flow−$5.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.3%
1M
−51.8%
YTD
−94.4%
1Y
−92.6%
From 52W high
−96.4%
From 52W low
+15.1%
$2
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Adagio Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Issuance
63
Accruals
29
Volatility
28
Momentum
24
Revisions
20
Quality
9
Value
1

Growth (95): Sales and profits are climbing, and climbing faster than before.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ADGM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADGM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26ADGMHigh $120Median $120Low $120

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$120
Low
$120
Median
$120
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy$3.00
14 Apr 2026Piper SandlerInitiatesOverweight—
2 Dec 2025Lake StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ADGM.

Market Radar

This page is one stock. Monday covers all of them.

ADGM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ADGM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Adagio Medical Holdings, Inc. returned −92.6% against +6.9% for the S&P 500, dividends included.

ADGM vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26ADGMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADGM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−35.5%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adagio Medical Holdings, Inc. has a market value of $1.7M and an enterprise value of $19.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$27.1M.

  • Diluted earnings per share, trailing twelve months: −$1.48.

  • Free cash flow in the twelve months to 30 June 2026: −$16.6M.

  • Shares outstanding: 22.2M.

  • Adagio Medical Holdings, Inc. employs 41 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ADGM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ADGMAdagio Medical Holdings, Inc.$1.7M24
NXLNexalin Technology, Inc.$1.7M24
AMIXAutonomix Medical, Inc.$1.7M31
CODXCo-Diagnostics, Inc.$1.7M32
GCTKGlucoTrack, Inc.$1.6M—
VVOSVivos Therapeutics, Inc.$1.8M43
PFSAProfusa, Inc.$1.8M19

Take a look at ADGM’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Adagio Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ADGM

What is the ADGM stock price forecast for 2026-2027?

The median 12-month analyst price target for Adagio Medical Holdings, Inc. is $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADGM stock a buy right now?

Of the 1 analyst covering Adagio Medical Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adagio Medical Holdings, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADGM?

As at 21 Nov 2026, Adagio Medical Holdings, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will ADGM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $120, and Ticker Nerd's factor model ranks Adagio Medical Holdings, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADGM stock forecast for 2030?

No analyst covering Adagio Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADGM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $120 to $120 over the next 12 months.

How has ADGM stock performed over the past year?

Adagio Medical Holdings, Inc. returned -92.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adagio Medical Holdings, Inc. do?

Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias. Its current portfolio includes the iCLAS atrial ultra-low temperature ablation system, the vCLAS ventricular ultra-low temperature catheter platform, and Cryopulse pulsed field cryoablation catheters.

Company

About Adagio Medical Holdings, Inc.

Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias. Its current portfolio includes the iCLAS atrial ultra-low temperature ablation system, the vCLAS ventricular ultra-low temperature catheter platform, and Cryopulse pulsed field cryoablation catheters. These technologies are designed to support physicians treating rhythm disorders such as atrial fibrillation and ventricular tachycardia, with an emphasis on delivering targeted lesion creation in cardiac tissue. Adagio Medical Holdings, Inc. operates as a healthcare device company serving the electrophysiology market, where catheter ablation plays an important role in minimally invasive heart rhythm management. Headquartered in Laguna Hills, California, the company concentrates on clinical and commercial use cases across cardiac arrhythmia care.

CEO Mr. Todd Usen · 41 employees · United States · https://adagiomedical.com